Dr. Matthieu Rouffet is a medicinal chemist who was born and raised in France. After completing his Ph.D. in pharmaceutical chemistry at the University of Reims, he moved to San Diego to start a postdoctoral fellowship position at UCSD under the supervision of Professor Seth. M. Cohen. During that time, he worked on the development of inhibitors of biologically relevant targets.
Education
- Ph.D., Organic Chemistry, School of Pharmacy, Reims, France
- M.S., Organic Chemistry, University of Reims, France
- B.S., Chemistry, University of Reims, France
Courses Taught
- Intro to General, Organic, and Biological Chemistry 鈥� CHE 1003
- Intro to General, Organic, and Biological Chemistry Lab 鈥� CHE 1003L
- Organic Chemistry I Lab 鈥� CHE 2094L
- Bioinorganic Chemistry 鈥� CHE 4066
- Chemistry Seminar 鈥� CHE 4095
- Research in Chemistry 鈥� CHE 4099
- Physical Science 鈥� PSC 1014
- Advanced Organic Chemistry 鈥� CHE 4053
Experience in Field
- Research interest: synthesis and biological evaluation of metal binding inhibitors of metalloenzymes involved in diseases such as anthrax infection, malaria, and tuberculosis
- 国产剧麻豆剧 (San Diego, CA), Associate Professor, 2011 鈥� present
- University of California at San Diego (San Diego, CA), Postdoctoral Associate, 2009 鈥� 2011
- School of Pharmacy, Reims (Reims, France), Graduate Researcher, 2005 鈥� 2008
- University of York (United Kingdom), Undergraduate Researcher, 2004
Professional and Community Involvement
- Member, American Chemical Society, 2009 鈥� present
- Member, French Chemical Society, 2005 鈥� 2008
Awards and Honors
- Ph.D. scholarship from the Region of Champagne-Ardennes (France), 2005 鈥� 2008
- Master of Science merit scholarship, 2004 鈥� 2005
Dissertations, Presentations, and Publications
- "Perez, C.; Li, J.; Parlati, F.; Rouffet, M.; Ma, Y.; Mackinnon, A, L,; Chou, T,; Deshaies, R, J.; and Cohen, S. M. ""Discovery of an Inhibitor of the Proteasome Subunit Rpn11.""
- J. Med. Chem., 2017, accepted"
- Abass, G.; Elson, D.; Dorrell, M.; Rouffet, M. 鈥淭owards the synthesis of MTX-phenylalanine derivatives for the treatment of glioblastoma in antibody-directed enzyme prodrug therapy鈥� American Chemical Society National Meeting, San Diego, 2016. (Poster)
- "Voss, C. L.; Rouffet, M. 鈥淒esign and Synthesis of 2-(2-sulfonamido)phenylbenzimidazole derivatives as Potential IspF Inhibitors.鈥�
- American Chemical Society National Meeting, San Diego, 2016. (Poster)"
- Tanakit, A.; Rouffet, M.; Martin, D. P. and Cohen, S. M, 鈥淚nvestigating chelating sulfonamides and their use in metalloproteinase inhibitors鈥�, Dalton Trans., 2012, 41, 6507. (paper)
- Rouffet, M. and Cohen, S. M., 鈥淓merging trends in metalloprotein inhibition鈥�, Dalton Trans., 2011, 40, 3445 (paper)
- Zhou, H.; Parlati, F.; Rouffet, M.; Emberley, E.; Deshaies, R. J.; Cohen, S. M. "Compositions and methods for jamm protein inhibition." 2014, US 20140235548 A1 (patent)
- Rouffet, M.; De Oliveira, C. A. F.; Udi, Y.; Agrawal A.; Sagi, I.; McCammon, J. A. and Cohen, S.M. 鈥淔rom Sensors to Silencers: Quinoline- and Benzimidazole-Sulfonamides as Inhibitors for Zinc Proteases.鈥� J. Am. Chem. Soc., 2010, 132, 8232鈥�8233 (paper)
